Glenmark has received FDA clearance for its generic version of Alcon’s Pataday Once Daily Relief Ophthalmic Solution, olopatadine hydrochloride ophthalmic solution 0.2% over-the-counter (OTC). This generic medication will be distributed in the US by Glenmark Therapeutics, USA. The Pataday Once Daily Relief Ophthalmic Solution market had sales of approximately $50.7 million in the latest 52 weeks period ending February 22, 2025, according to Nielsen syndicated data. Marc Kikuchi, president and business head of North America at Glenmark, expressed his company’s excitement to expand its OTC ophthalmic portfolio, emphasizing its commitment to meeting market needs and providing high-quality OTC solutions for customers.
The approval of Glenmark’s olopatadine hydrochloride ophthalmic solution 0.2% OTC marks another significant milestone for the company, which has been actively expanding its presence in the OTC market. The company has a strong pipeline of products in various stages of development, with a focus on providing high-quality, affordable, and innovative solutions to patients. The availability of this generic medication will cater to the growing demand for affordable and effective eye care products, bringing relief to patients suffering from allergies, itchy, red, and watery eyes.
By offering a generic version of Pataday, Glenmark is expected to increasing access to this medication, making it more convenient and cost-effective for patients to manage their ophthalmic conditions. The company’s commitment to innovation, quality, and customer satisfaction has earned it a reputation as a reliable player in the pharmaceutical industry, further solidifying its position as a major player in the OTC market.